United States · Platforms & data · Stocktwits

Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027

Published by Stocktwits · United States 11 h ago

The drugmaker reported a diluted net loss of $0.31 per share in Q3, beating analysts’ expectations of a $0.41 per share loss, according to Fiscal.ai. Compass ended September with…

Read the full article on Stocktwits Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)

Also worth reading

Seeking Alpha

Renew outlines FY2027 adjusted EBITDA guidance of INR 105B to INR 109B as take-private process targets Q1 2027 close

MarketWatch

Want to help your adult kids and grandkids? Give them money while you’re still alive.

The Motley Fool

Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027

Share

Also worth reading

Renew outlines FY2027 adjusted EBITDA guidance of INR 105B to INR 109B as take-private process targets Q1 2027 close

Want to help your adult kids and grandkids? Give them money while you’re still alive.

Where Will QuantumScape Stock Be in 5 Years?

Regal Rexnord Q3 2026 slides: organic growth accelerates to 6.1%

Stock market after midterm elections: What S&P 500 history shows

Myro (MYRO) Price Prediction: 2025, 2026, 2030